2'-Substituted Nicotine Compounds for Selective nAChR Stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nicotinic acetylcholine receptor (nAChR) agonists, including nicotine, lack selective activity on alpha7 and alpha4beta2 receptors, limiting their therapeutic potential for cognitive disorders and addiction treatment due to non-specific stimulation of nAChRs, which can cause adverse effects.
Innovation Solution
Development of 2'-substituted nicotine compounds, azetidine compounds, and ether-linked nicotine compounds that selectively stimulate alpha7 and/or alpha4beta2 receptors through specific structural modifications, such as methylation and substitution at key sites on the nicotine molecule, allowing for concurrent stimulation of both receptor subtypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nicotine or conventional nAChR agonists are used to treat cognitive disorders and addiction, then nAChR stimulation occurs, but selective activity on alpha7 and alpha4beta2 receptors is lacking leading to non-specific stimulation and adverse effects
Solution Approach 1:
The patent applies local quality by introducing specific substituents at defined positions on the nicotine scaffold. Compound (1) features a substituent R1 at position 2' on the pyrrolidine ring and R2 at position 6' on the pyridine ring, creating localized structural modifications that confer selective affinity for alpha7 and alpha4beta2 receptors while maintaining the core nicotine pharmacophore. This targeted substitution strategy enables differential receptor interaction without requiring complete structural redesign.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical nature of substituents R1 and R2 in compound (1). Different substituent types (alkyl, aryl, heteroaryl, electron-withdrawing or electron-donating groups) are introduced to fine-tune the balance between alpha7 and alpha4beta2 receptor selectivity. This parametric approach allows optimization of receptor binding characteristics while controlling for adverse effects from non-specific nAChR subtype stimulation.
2Reliability
If structural modifications are made to nicotine to achieve receptor selectivity, then therapeutic potential is improved, but the complexity of compound design and synthesis increases
Solution Approach 1:
The patent applies universality by designing compound (1) as a multi-functional nicotine analog that simultaneously targets both alpha7 and alpha4beta2 receptors with selective affinity. The core nicotine scaffold maintains the essential pharmacophore for nAChR binding, while the strategic substituents R1 and R2 provide dual functionality: enhancing receptor selectivity and enabling treatment of multiple conditions including cognitive disorders and addiction. This multi-functional design achieves therapeutic versatility without requiring multiple separate compounds.
Solution Approach 2:
The patent employs segmentation by dividing the nicotine molecule into distinct functional regions: the core pyrrolidine-pyridine scaffold that provides baseline nAChR affinity, the 2'-position substituent R1 that influences receptor subtype selectivity, and the 6' -position substituent R2 that fine-tunes binding characteristics. This segmented approach to molecular design allows independent optimization of each region's contribution to overall receptor selectivity and therapeutic efficacy.
Data Source
Figure 1.1
Figure 1.2
Figure 2.1
AI summary
Embodiments of the present disclosure provide for compounds such as those shown in FIG. 1.1 (compounds A, B, C, and D), 2'substituted nicotine compounds, azetidine compounds, ether linked nicotine compounds (FIG. 1.2, compounds E, F, G, and H), methods of synthesis of the compounds, methods of treatment of a condition using compounds A, B, C, D, 2'substituted nicotine compounds, azetidine compounds, or ether linked nicotine compounds, methods of selectively stimulating alpha7 nAChR and/or alpha4beta2 receptors, and the like.